- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04649723
Drug-Drug Interaction of SHR1459 With a Strong CYP3A Index Inducer (Rifampicin)
January 7, 2021 updated by: Jiangsu HengRui Medicine Co., Ltd.
A Single-Center, Single-Arm, Open-Label, Fixed-Sequence Phase I Drug-Drug Interaction Clinical Study of the Effect of Rifampicin on Pharmacokinetics of SHR1459 in Chinese Healthy Subjects.
This drug-drug interaction (DDI) study had been designed to investigate the effect of a strong CYP 3A index fan-inducer rifampicin on the pharmacokinetics of SHR1459 in Chinese healthy volunteers.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 201203
- Jiangsu HengRui Medicine Co., Ltd.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;
- Ability to complete the study as required by the protocol;
- Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
- Body weight ≥50 kg for male and≥ 45 kg for female, and body mass index (BMI) within the range of 19 ~ 26 kg /m2 (including 19 and 26);
- In females, documented surgical sterilization, postmenopausal status for at least 1 year (follicle stimulating hormone [FSH] > 40 mIU/mL serum at Screening), or agreement to use an approved form of contraception
- In males, agreement to avoid sperm donation for 3 months days after the dose of SHR1459
- Liver function test results must be below the upper limit of normal.
- Participants must agree to refrain from donation of whole blood and other blood products from 90 days prior to screening.
- Heart rate ≥60 bpm.
- GFR≥90 mL/min/1.73m2.
Exclusion Criteria:
- Loss of more than 400 mL blood during the 3 months before the trial (eg, as a blood donor)
- Allergic constitution;
- History of drug use, or drug abuse screening positive;
- Alcoholic or often drinkers;
- A smoker with 5 cigarettes per day for more than 90 days;
- Positive serology for hepatitis B surface antigen (HBsAg) and HCV (healthy participants), anti-treponema pallidum virus (TP), or antihuman immunodeficiency virus (HIV) Type 1 and Type 2 (all subjects)
- Use of any drugs or substances known to be inhibitors or inducers of CYP3A within 90 days from the first dose or 5 half-lives, if known, of the drugs or substances, whichever is greater, prior to SHR1459 administration and during the study.
- A clear medical history of important primary organ diseases such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system.
- Abnormal clinical laboratory tests and clinical significance judged by the investigator or other clinical findings showing the following diseases, including but not limited to gastrointestinal tract, kidney, liver, nerve, blood, endocrine, tumor, lung, immune, mental or cardiovascular and cerebrovascular diseases.
- Use of grapefruit or marmalade in 2 weeks prior to admission to the clinical unit, as reported by the subject.
- Major surgery within 6 months before screening.
- Woman in breastfeeding and pregnancy and with egg donation plan, and man with sperm donation plan in 6 months after follow-up in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rifampicin 600 mg + SHR1459 Tablets 200 mg
|
single oral dose, 600 mg, fasted.
single oral dose, 200 mg, fasted.
|
Active Comparator: SHR1459 tablets 200 mg
|
single oral dose, 200 mg, fasted.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Plasma Concentration (Cmax) for SHR1459.
Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
Area Under the Plasma Concentration-time Curve from 0 to any time before the last quantifiable concentration (AUC0-t) for SHR1459.
Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
Area Under the Plasma Concentration-time Curve from 0 to infinite time (AUCinf) for SHR1459.
Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence and severity of adverse events/serious adverse events (based on NCI-CTCAE 5.0): Laboratory indicators, 12-lead electrocardiogram (ECG), physical examination, vital signs, etc.
Time Frame: Baseline up to 14 days post last dose, up to approximately 2 month
|
Baseline up to 14 days post last dose, up to approximately 2 month
|
Other pharmacokinetics parameters of SHR1459: Tmax, T1/2, CL, Vd, etc
Time Frame: predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
predose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24h for Day1 and Day9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 24, 2020
Primary Completion (Actual)
December 14, 2020
Study Completion (Actual)
December 14, 2020
Study Registration Dates
First Submitted
November 10, 2020
First Submitted That Met QC Criteria
November 25, 2020
First Posted (Actual)
December 2, 2020
Study Record Updates
Last Update Posted (Actual)
January 11, 2021
Last Update Submitted That Met QC Criteria
January 7, 2021
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Leprostatic Agents
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Rifampin
Other Study ID Numbers
- SHR1459-I-105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects, Drug-drug Interaction, Pharmacokinetics, SHR1459
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Pharmacokinetics | Drug-Drug InteractionFrance
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)Germany
-
Daiichi Sankyo Co., Ltd.CompletedHealthy Subjects | Pharmacokinetics | Drug-drug Interaction | QuizartinibUnited States
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)Germany
-
Daiichi Sankyo Co., Ltd.CompletedHealthy Subjects | Pharmacokinetics | Drug-drug Interaction | QuizartinibUnited States
-
Astellas Pharma Europe B.V.Medivation, Inc.CompletedHealthy Subjects | Drug-Drug Interaction (DDI) | Pharmacokinetics of EnzalutamideGermany
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Pharmacokinetics | DDI (Drug-Drug Interaction)Germany
-
Astellas Pharma Europe B.V.Cubist Pharmaceuticals LLCCompletedHealthy Subjects | Drug-Drug Interaction (DDI) | Intestinal Absorption | Pharmacokinetics of Rosuvastatin | Pharmacokinetics of FidaxomicinGermany
-
Jiangsu HengRui Medicine Co., Ltd.UnknownHealthy Subjects, Drug-drug Interaction, PyrotinibChina
-
Astellas Pharma Europe B.V.CompletedHealthy Subjects | Drug-Drug Interaction (DDI)United Kingdom
Clinical Trials on Rifampin
-
McGill University Health Centre/Research Institute...Canadian Institutes of Health Research (CIHR)Active, not recruitingLatent TuberculosisCanada, Indonesia, Vietnam
-
Pontificia Universidad Catolica de ChileSociedad Chilena de PediatríaUnknownRespiratory Distress SyndromeChile
-
Centre Hospitalier Universitaire, AmiensTerminatedAcute Respiratory Distress SyndromeFrance
-
Windtree TherapeuticsCompletedAcute Hypoxemic Respiratory FailureUnited States, Chile
-
CTI BioPharmaCovanceCompleted
-
Austin HealthCompletedHypersensitivity, Immediate | Hypersensitivity, Delayed | Hypersensitivity ResponseUnited States, Australia, Canada
-
Gangnam Severance HospitalCompletedAcinetobacter Infections | Colistin | Rifampin
-
Henry Ford Health SystemCompletedHidradenitis SuppurativaUnited States
-
Daping Hospital and the Research Institute of Surgery...Children's Hospital of Chongqing Medical UniversityRecruitingPreterm Birth | Acute Respiratory Distress Syndrome | Respiratory Distress Syndrome | Surfactant DysfunctionChina
-
University of South FloridaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedArthritis, Reactive | Reiter DiseaseUnited States, Canada